Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?

The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system.Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sun...

Full description

Saved in:
Bibliographic Details
Published inJournal of Cancer Vol. 2; no. 1; pp. 333 - 338
Main Authors Porta, Camillo, Paglino, Chiara, Imarisio, Ilaria, Ganini, Carlo, Pedrazzoli, Paolo
Format Journal Article
LanguageEnglish
Published Australia Ivyspring International Publisher 01.01.2011
Subjects
Review
kidney cancer
cellular therapies
multikinase inhibitors
immunology
Online AccessGet full text

Cover

More Information
Summary:The multikinase inhibitors Sunitinib and Sorafenib not only inhibit angiogenesis and tumor growth, but also have the potential of interacting with the function of the immune system.Presently available data seem to suggest that Sorafenib may exert immune suppressive effects, whilst the effects of Sunitinib are not so clear, being immune stimulatory in the vast majority - but not all - the studies reported.Trials of combination of these multikinase inhibitors with different types of immune manipulation - and cellular therapies in particular - should be rationally designed taking into account all these complex effects, which ultimately deserve further insights.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conflict of Interest: The authors have declared that no conflict of interest exists.
ISSN:1837-9664
1837-9664
DOI:10.7150/jca.2.333